The Institute of Cancer Research
Discovered more cancer drugs than any other academic institution, including abiraterone and the clinical use of PARP inhibitors.
Abiraterone (de Bono), olaparib in BRCA (Tutt, Ashworth synthetic lethality), capivasertib origins, Cancer Therapeutics Unit; partner of the Royal Marsden.
- Drug discovery
- Prostate cancer
- Synthetic lethality
Led OlympiA, the trial that showed a year of olaparib after surgery improves survival in BRCA-mutated breast cancer.
Co-discovered the synthetic lethality between PARP inhibition and BRCA loss that underlies PARP inhibitor therapy.
Melanoma and kidney cancer trialist who co-led CheckMate 067, the trial with 10-year immunotherapy survival data.
Johann de Bono led the trials that brought abiraterone and olaparib to prostate cancer patients.
Kevin Harrington is a head and neck oncologist and oncolytic virus pioneer who led the OPTiM trial of T-VEC.
Epigenetics researcher who leads the ICR, the academic institution with the most cancer drug discoveries.
Showed that childhood leukaemia begins before birth and framed cancer as an evolutionary process.
Nicholas James is chief investigator of STAMPEDE, the platform trial that reshaped treatment of advanced prostate cancer.
Breast cancer researcher who turned ctDNA into a tool for choosing treatment, leading SERENA-6 and CAPItello-291.
Drug-discovery pioneer who built the ICR's Cancer Therapeutics Unit and championed the 'pharmacological audit trail'.
Uwe Oelfke is the radiotherapy physicist behind the Marsden's pioneering MR-linac programme.
Patients with head and neck squamous cell cancer that has recurred or spread should be treated first with pembrolizumab: alone if their tumour is strongly PD-L1 positive and they can wait for a slower response, or with chemotherapy if the tumour is bulky or PD-L1 low. Cetuximab-based chemotherapy is no longer the default. Long-term follow-up shows a small but real group of patients alive at four to five years, which was almost unheard of before.
Men diagnosed with prostate cancer that has already spread, or that is locally advanced and high risk, should start abiraterone (or another androgen-receptor pathway inhibitor) at the same time as testosterone suppression rather than waiting for resistance. This roughly halves the risk of death over several years. The same platform later showed that docetaxel chemotherapy and, in high-volume metastatic disease, triple therapy also help, and that abiraterone benefits men with high-risk disease treated with radiotherapy.
Pages like this
not linked directly; found by shared links- TechnologyPARP inhibitors
Shares Christopher Lord, Andrew Tutt, Johann de Bono, Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre.
- IdeaRegional translational institutes with academic GMP suites and IND teams
Shares Paul Workman, Scale up public drug development that takes academic assets to phase 1, The valley of death between lab and product.
- TrialCAPItello-281
Shares Capivasertib, Abiraterone acetate, Prostate cancer.
- TechnologyMR-guided adaptive radiotherapy
Shares Uwe Oelfke, Core-funded radiotherapy trials infrastructure with central quality assurance, The Royal Marsden, Prostate cancer.
- TrialPROfound
Shares Johann de Bono, Olaparib, Prostate cancer.
- InstitutionBroad Institute of MIT and Harvard
Shares A precompetitive consortium for the twenty hardest cancer targets, An open map of which cancer proteins any drug can stick to, Attack the backup copy when a tumour has lost the original gene, The valley of death between lab and product.
- TechnologySynthetic lethality approaches
Shares Christopher Lord, Attack the backup copy when a tumour has lost the original gene, DNA replication stress, Synthetic lethality.
- TrialOlympiA
Shares Andrew Tutt, Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre, Olaparib.